Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
Launched by WUHAN UNION HOSPITAL, CHINA · Dec 11, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The medical imaging data will be collected retrospectively and prospectively, and the blood samples and tumor tissues will be collected prospectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pathological examination confirmed lung adenocarcinoma
- • No other type of tumor was present
- • Common sensitive EGFR (Ex19Del L858R or combined with other sites) mutations have been identified
- • Receive targeted therapy with or without chemotherapy as first-line treatment
- • ≥ 18 years and ≤80 years old
- Exclusion Criteria:
- • History of other malignant tumors
- • Irregular treatment or poor compliance
- • Incomplete clinical information or lost to follow-up
About Wuhan Union Hospital, China
Wuhan Union Hospital, affiliated with Huazhong University of Science and Technology, is a leading medical institution located in Wuhan, China. Renowned for its comprehensive healthcare services and advanced research capabilities, the hospital plays a pivotal role in clinical trials aimed at enhancing medical knowledge and patient care. With a commitment to innovation and excellence, Wuhan Union Hospital collaborates with various stakeholders to conduct rigorous and ethically sound clinical research, contributing significantly to the advancement of medical science and public health both domestically and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported